2962 related articles for article (PubMed ID: 31694698)
1. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
2. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
3. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
Zhang Y; Fang Y; Wu J; Huang G; Bin J; Liao Y; Shi M; Liao W; Huang N
Front Pharmacol; 2022; 13():817662. PubMed ID: 35431928
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
6. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
7. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract][Full Text] [Related]
9. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
10. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS.
Chen C; Chen T; Liang J; Guo X; Xu J; Zheng Y; Guo Z; Chi L; Wei L; Chen X; Ye X; He J
Front Pharmacol; 2021; 12():616505. PubMed ID: 33643048
[TBL] [Abstract][Full Text] [Related]
15. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wei Q; Wu X
Front Pharmacol; 2022; 13():986357. PubMed ID: 36408225
[No Abstract] [Full Text] [Related]
16. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
Liang X; Xiao H; Li H; Chen X; Li Y
Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
[TBL] [Abstract][Full Text] [Related]
17. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
[TBL] [Abstract][Full Text] [Related]
18. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
Johnson DB; Manouchehri A; Haugh AM; Quach HT; Balko JM; Lebrun-Vignes B; Mammen A; Moslehi JJ; Salem JE
J Immunother Cancer; 2019 May; 7(1):134. PubMed ID: 31118078
[TBL] [Abstract][Full Text] [Related]
19. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study.
Li N; Feng Y; Chen X; Li Y; Zhang C; Yin Y
Front Pharmacol; 2023; 14():1213608. PubMed ID: 38026965
[No Abstract] [Full Text] [Related]
20. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.
Cui C; Deng L; Wang W; Ren X; Wang Y; Cui W
Front Oncol; 2022; 12():941079. PubMed ID: 36059699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]